News

Brixton Biosciences' Neural Ice™ Therapy granted Breakthrough Device designation by the FDA
CAMBRIDGE, Massachusetts, Oct. 25, 2023 – Brixton Biosciences, a clinical-stage life sciences company developing novel therapies for chronic and acute pain, is delighted to announce that its groundbreaking Neural Ice™ Therapy has received the prestigious Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
Read more...‍

Brixton logo
TechnologyAboutLeadershipNewsContact
©2023 Brixton Biosciences. All rights reserved. | Privacy Policy | Terms of Use
This website describes our product, which has not been approved or cleared for marketing by the U.S. Food and Drug Administration and is considered an investigational device.